Roche acquires Telavant from Roivant and Pfizer for $7.25 billion
Telavant is a biopharmaceutical company developing RVT-3101, a late-stage drug candidate for inflammatory bowel disease (IBD).
Roche is a Swiss pharmaceutical giant with a strong portfolio of drugs for IBD, including Remicade and Entyvio.
The acquisition of Telavant will give Roche access to RVT-3101, a promising new drug for IBD.
RVT-3101 is a monoclonal antibody that targets p40, a protein that plays a role in inflammation.
RVT-3101 has shown promising results in clinical trials, and is expected to be submitted for regulatory approval in 2024.
RVT-3101 has shown promising results in clinical trials, and is expected to be submitted for regulatory approval in 2024.
IBD is a chronic inflammatory disease of the digestive tract that affects millions of people worldwide. There is no cure for IBD, but there are treatments that can help to manage the symptoms.